Immunotherapy Monitoring

The development of methods to propagate immune T-cells, and in particular tumor specific T-cells from the patients with cancer, lead to an important breakthrough; the identification of MAGE-1,a melanoma-specific antigen that stimulates human T-cells in-vitro. With antigen specific T-cells as a reagents, it was possible to clone the MAGE-1 studies showed that the human immune system can respond tumor antigens, and the findings stimulated a productive effort to discover tumor antigens. The result is a long and still-growing list of antigens from a variety of tumor that could serve a variety of tumor’s that could serve as targets for treatment.

  • Parameters for Immune Response
  • Biomarker Development for Ipilimumab and Prostate Gvaxtreatment
  • Development of Biomarkers for an Engineered Anti PDL1 Antibody MPDL3280A and Clinical Activity
  • Microenvironment Screening Platform Captures Biological Responses of Cancer Therapeutics
  • Radiotherapy and Chemotherapy with Dendritic Cell Immunotherapy in Glioblastoma Patients

Related Conference of Immunotherapy Monitoring

April 04-05, 2024

38th International Conference on Immunology

Madrid, Spain
May 23-24, 2024

18th International Conference on European Immunology

Zurich, Switzerland

Immunotherapy Monitoring Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in